Likmez Suspension not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Bacterial Infections
- Main trialPhase 2
- “This is an open-label, single-arm, pharmacokinetic and safety study of Likmez® in pediatric patients aged 12 months to \<4 years with anaerobic bacterial infection”In the company’s words, NCT07146217 on ClinicalTrials.gov
Other drugs for Bacterial Infections
- DTpaGSK · Phase 3
- 13-Valent Pneumococcal Polysaccharide Conjugate VaccineCanSino Biologics Inc. · Phase 3
- Group ACYW135 Meningococcal Conjugate VaccineSinovac Biotech Co., Ltd · Phase 3
- 20vPCVSanofi · Phase 3
- Pneumococcal Conjugate VaccineSanofi · Phase 3
- VLA15Pfizer · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Jul 2026 | Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026